Gilead(US:GILD) Benzingaยท2025-02-12 20:22Core Insights - Gilead Sciences reported fourth-quarter 2024 adjusted EPS of $1.90, exceeding the consensus estimate of $1.70, with sales rising 6% year-over-year to $7.57 billion, surpassing the consensus of $7.14 billion [1][2] Sales Performance - HIV sales increased by 16% to $5.45 billion, driven by demand, higher realized prices, and favorable inventory dynamics [1] - Biktarvy sales rose from $3.12 billion to $3.8 billion, while liver disease sales increased by 4% to $719 million, supported by a strong Livdelzi launch and increased HBV/HDV demand [2] Dividend and Guidance - Gilead increased its quarterly cash dividend by 2.6% to $0.79 per share [2] - The company expects 2025 adjusted EPS to be between $7.70 and $8.10, compared to the consensus of $7.58, and sales to range from $28.2 billion to $28.6 billion, against a consensus of $28.42 billion [3] Future Prospects - Gilead plans to launch lenacapavir for HIV PrEP in Summer 2025, which is expected to enhance its position in the PrEP market and improve patient adherence [4][5] - Analysts from Piper Sandler and Goldman Sachs express optimism regarding Gilead's upcoming lenacapavir launch and its potential impact on revenue [4][5] Analyst Sentiment - Needham maintains a Hold rating on Gilead, citing balanced risk/reward at current levels, but is growing more optimistic due to strong HIV business performance and improving profit margins [6][7] - Gilead's stock rose by 7.73% to $103.57 following the earnings report [7]